Nikko Asset Management Americas Has Lifted By $4.99 Million Its Hortonworks (HDP) Holding; Evoke Pharma (EVOK) Sentiment Is 1.63

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. The company has market cap of $30.67 million. It is developing Gimoti, a metoclopramide nasal spray, which completed Phase III clinical trials for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. It currently has negative earnings.

Nikko Asset Management Americas Inc increased Hortonworks Inc (HDP) stake by 46.26% reported in 2017Q3 SEC filing. Nikko Asset Management Americas Inc acquired 311,818 shares as Hortonworks Inc (HDP)’s stock rose 17.74%. The Nikko Asset Management Americas Inc holds 985,918 shares with $16.71 million value, up from 674,100 last quarter. Hortonworks Inc now has $1.44B valuation. The stock decreased 1.09% or $0.22 during the last trading session, reaching $19.89. About 574,867 shares traded. Hortonworks, Inc. (NASDAQ:HDP) has risen 25.48% since March 8, 2017 and is uptrending. It has outperformed by 8.78% the S&P500.

Knoll Capital Management Lp holds 0.64% of its portfolio in Evoke Pharma, Inc. for 225,000 shares. Sphera Funds Management Ltd. owns 571,022 shares or 0.27% of their US portfolio. Moreover, Family Management Corp has 0.02% invested in the company for 10,425 shares. The Michigan-based State Treasurer State Of Michigan has invested 0.01% in the stock. Bank Of America Corp De, a North Carolina-based fund reported 10,000 shares.

Analysts await Evoke Pharma, Inc. (NASDAQ:EVOK) to report earnings on March, 21. They expect $-0.22 EPS, down 22.22% or $0.04 from last year’s $-0.18 per share. After $-0.24 actual EPS reported by Evoke Pharma, Inc. for the previous quarter, Wall Street now forecasts -8.33% EPS growth.

Ratings analysis reveals 50% of Evoke Pharma’s analysts are positive. Out of 2 Wall Street analysts rating Evoke Pharma, 1 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $2.5 while the high is $8.0. The stock’s average target of $5.25 is 163.82% above today’s ($1.99) share price. EVOK was included in 2 notes of analysts from December 23, 2016. The firm earned “Buy” rating on Monday, January 30 by Laidlaw. The firm has “Neutral” rating by Rodman & Renshaw given on Friday, December 23.

The stock increased 3.11% or $0.06 during the last trading session, reaching $1.99. About 115,108 shares traded or 17.67% up from the average. Evoke Pharma, Inc. (EVOK) has declined 51.99% since March 8, 2017 and is downtrending. It has underperformed by 68.69% the S&P500.

Nikko Asset Management Americas Inc decreased Monsanto Co (NYSE:MON) stake by 33,600 shares to 417,100 valued at $49.98 million in 2017Q3. It also reduced Archer (NYSE:ADM) stake by 33,300 shares and now owns 380,199 shares. Cf Industries Holdings Inc (NYSE:CF) was reduced too.